News/ News/ Oncology Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC Richard Staines cancer, Exelixis, Iconic Therapeutics, Zymeworks 0 Comment Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, Share X Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC https://pharmaphorum.com/news/exelixis-takes-20m-option-iconic-zymeworks-cancer-adc/
